• Explore /
  • Poster
  • / Clinical activity and safety of the RET inhibitor pralsetinib in patients with <em>RET</em> fusion-positive solid tumors: Update from the ARROW trial.

Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.

Abstract Video & Slides Poster

Authors

Vivek Subbiah

Vivek Subbiah

University of Texas MD Anderson Cancer Center, Houston, TX

Vivek Subbiah , Philippe A. Cassier , Salvatore Siena , Guzman Alonso , Luis G. Paz-Ares , Pilar Garrido , Ernest Nadal , Giuseppe Curigliano , Jacqueline Vuky , Gilberto Lopes , Gregory Peter Kalemkerian , Daniel W. Bowles , Mahesh Seetharam , Jianhua Chang , Hui Zhang , Chaoyang Ye , Jennifer Green , Alena Zalutskaya , Martin H. Schuler , Yun Fan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT03037385

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3079)

DOI

10.1200/JCO.2021.39.15_suppl.3079

Abstract #

3079

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Justin F. Gainor

First Author: Alissa Jamie Cooper

First Author: Sanjay Popat

First Author: Giuseppe Curigliano